U.S. Markets open in 6 hrs 55 mins
  • S&P Futures

    3,811.00
    -5.75 (-0.15%)
     
  • Dow Futures

    31,224.00
    -12.00 (-0.04%)
     
  • Nasdaq Futures

    12,660.00
    -21.75 (-0.17%)
     
  • Russell 2000 Futures

    2,201.40
    -4.40 (-0.20%)
     
  • Crude Oil

    61.91
    +0.63 (+1.03%)
     
  • Gold

    1,717.90
    +2.10 (+0.12%)
     
  • Silver

    26.26
    -0.12 (-0.46%)
     
  • EUR/USD

    1.2060
    -0.0007 (-0.0603%)
     
  • 10-Yr Bond

    1.4700
    0.0000 (0.00%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3965
    +0.0012 (+0.0880%)
     
  • USD/JPY

    107.1320
    +0.1300 (+0.1215%)
     
  • BTC-USD

    49,747.37
    +931.98 (+1.91%)
     
  • CMC Crypto 200

    995.96
    +7.86 (+0.80%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    28,930.11
    -628.99 (-2.13%)
     

Celsion: Q3 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

 

Shares of Celsion (NASDAQ:CLSN) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share increased 32.00% over the past year to ($0.17), which missed the estimate of ($0.13).

Revenue of $125,000 unchanged by 0.00% year over year, which beat the estimate of $80,000.

Outlook

Earnings guidance hasn't been issued by the company for now.

Celsion hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Nov 16, 2020

View more earnings on CLSN

Time: 11:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/n6e4r5nw

Price Action

Company's 52-week high was at $6.50

52-week low: $0.43

Price action over last quarter: down 51.53%

Company Overview

Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.